Market Overview

FDA Approves Use Of Zika Virus Blood Screener From Hologic And Grifols

Related HOLX
The Daily Biotech Pulse: Hologic, Celgene Earnings, FDA To Rule On Alkermes Depression Drug
The Daily Biotech Pulse: Roche Scraps Alzheimer's Disease Trials, Amgen Issues Weak Guidance
Hologic HIV test nabs dual claims in Europe (Seeking Alpha)
Related GRFS
33 Stocks Moving In Friday's Pre-Market Session
Rigel Rises On European Marketing Agreement For Autoimmune Drug

Hologic Inc (NASDAQ: HOLX) and Grifols, S.A. (NASDAQ: GRFS) announced Monday that they won FDA approval for the use of the Procleix Zika virus blood screening assay.

U.S. blood centers will use Procleix to screen blood donations in the Southern US and other areas potentially affected by the virus. The American Red Cross has partnered with Hologic and Grifols to perform the Procleix Zika Virus assay investigational study.

Hologic and Grifols shares closed Monday at $34.14 and $15.58, respectively, both up about 1 percent from Friday's close.

Posted-In: Zika Zika VirusBiotech News Health Care FDA Media General


Related Articles (HOLX + GRFS)

View Comments and Join the Discussion!

Negative Fintech Landscape Providing Buying Opportunity?

President Obama On Returning To The Job Market: 'I'm Gonna Get On LinkedIn'